reference_id	platform	category	competitor_type	primary_user	entry_task	moat	openness	wet_lab_loop	disease_specificity	evidence_transparency	adoption_priority	observed_capability	practice_to_adopt	practice_not_to_copy	local_equivalent	nmd_vcell_advantage	current_gap	adoption_state	sources
LANDSCAPE-ARC-VCI	Arc Virtual Cell Initiative · STATE · Stack · VCC	FULL_STACK_VIRTUAL_CELL	DIRECT	ML developers and computational biologists	Train or benchmark a perturbation model	DATA_MODEL_BENCHMARK	OPEN_RESEARCH	PARTIAL	GENERAL_BIOLOGY	HIGH	P0	Connects large observational and perturbational atlases, open models, standardized evaluation and a held-out challenge. Stack adds in-context single-cell modeling; the 2025 challenge retained simple baselines and exposed generalization failures.	Bind every prediction to a frozen task, hidden or sealed outcomes, permanent simple baselines and a ModelRun record.	Do not present Arc-scale data, leaderboards or generalization as local capability.	Data Universe | ModelRun registry | Benchmark dashboard	Disease-specific evidence governance, explicit missing outcomes, candidate Study Cards and preservation of negative runs.	No Arc-scale training corpus, no locally executed STATE or Stack adapter and no disease-relevant held-out perturbation outcomes.	PARTIAL_PRACTICE_ADOPTED_MODEL_NOT_INHERITED	https://arcinstitute.org/virtual-cell-initiative | https://arcinstitute.org/news/foundation-model-stack | https://arcinstitute.org/news/virtual-cell-challenge-2025-wrap-up
LANDSCAPE-CZI-VCP	CZI / Biohub Virtual Cells Platform	MODEL_DATA_BENCHMARK_PLATFORM	DIRECT	Biologists and ML developers	Find data, select a model, run or compare	MODEL_DATA_BENCHMARK_WORKSPACE	OPEN_PLATFORM	NO	GENERAL_BIOLOGY	HIGH	P0	Publishes model cards, datasets, benchmarks, CLI access and hosted workflows in one ecosystem, including TranscriptFormer and the context-specific scLDM.CD4 perturbation model.	Use one adapter and metadata contract across data discovery, local execution, benchmark reporting and web presentation.	Do not build a broad model marketplace before disease workflows and adapters are stable.	Dataset registry | Model cards | ModelRun registry | Virtual Cell Studio	A narrower neuromuscular decision loop with explicit claim ceilings and source-to-experiment traceability.	NMD-VCell has a run ledger but not a unified executable adapter layer or hosted inference workspace.	MODEL_RUN_LEDGER_RELEASED_ADAPTER_LAYER_NEXT	https://virtualcellmodels.cziscience.com/ | https://virtualcellmodels.cziscience.com/benchmarks | https://virtualcellmodels.cziscience.com/models
LANDSCAPE-CELLXGENE	CZ CELLxGENE Discover · Explorer · Census	SINGLE_CELL_DATA_PLATFORM	ADJACENT	Single-cell biologists	Find and explore a cell dataset	STANDARDIZED_DATA_DISCOVERY	OPEN_PLATFORM	NO	GENERAL_BIOLOGY	HIGH	P1	Provides versioned, ontology-harmonized single-cell data with low-latency metadata queries, source H5AD access and interoperable AnnData, Seurat and SingleCellExperiment slices.	Make dataset, donor, disease, state, batch and gene selections resolve to stable source objects and exportable analysis units.	Do not treat cell counts as independent biological replication.	Cell Context Map | Dataset registry	Neuromuscular disease interpretation and donor-aware claim ceilings rather than a general atlas browser.	The current Cell Context Explorer is a typed context registry, not yet a donor-level cell browser over imported matrices.	CONTEXT_REGISTRY_RELEASED_CELL_OBJECT_IMPORT_NEXT	https://chanzuckerberg.github.io/cellxgene-census/index | https://cellxgene.cziscience.com/docs/01__CellxGene
LANDSCAPE-OPEN-TARGETS	Open Targets Platform	TARGET_DISEASE_ENTITY_GRAPH	ADJACENT	Target and translational researchers	Inspect a target–disease relationship	ENTITY_RELATION_EVIDENCE	OPEN_PLATFORM	NO	GENERAL_DISEASE	HIGH	P0	Exposes source-provenanced target, disease, drug and association entities through a web interface, downloads, GraphQL and a versioned official MCP server.	Keep stable entity identifiers, release metadata, source-level provenance and machine interfaces synchronized.	Do not collapse heterogeneous evidence into one opaque target score.	Gene records | Disease atlas | Evidence graph	Cell-context, perturbation-run and prospective-study objects specialized for neuromuscular research.	NMD-VCell has linked objects but lacks a general graph query or agent interface across every object type.	PARTIAL_OBJECT_GRAPH_RELEASED_QUERY_LAYER_NEXT	https://platform.opentargets.org/ | https://api.platform.opentargets.org/ | https://mcp.platform.opentargets.org/
LANDSCAPE-DEPMAP	DepMap Portal	FUNCTIONAL_DEPENDENCY_PLATFORM	ADJACENT	Functional genomics researchers	Query dependency in a model context	RECURRING_FUNCTIONAL_DATA	OPEN_DATA_PORTAL	PARTIAL	CANCER	HIGH	P2	Combines recurring public CRISPR dependency releases, molecular characterization, model metadata, downloads and experimental APIs.	Version data releases, model contexts and mapping files together, and expose historical release identities.	Do not relabel cancer-cell dependency as neuromuscular efficacy.	External context evidence | Source buckets	Disease-specific evidence boundaries prevent cancer-cell dependency from being relabeled as muscle efficacy.	DepMap can add contextual dependency evidence, but it is not direct DMD muscle perturbation outcome.	REFERENCE_DATA_ONLY_NO_DMD_INHERITANCE	https://depmap.org/portal/data_page/?tab=allData | https://depmap.org/portal/api/
LANDSCAPE-VITESSCE	Vitessce	LINKED_SINGLE_CELL_VISUALIZATION	INFRASTRUCTURE	Single-cell and spatial analysts	Compose linked views over registered objects	LINKED_VISUAL_CONFIGURATION	OPEN_SOURCE	NO	GENERAL_BIOLOGY	MEDIUM	P2	Uses JSON view configurations to coordinate embeddings, expression matrices, spatial images and controls over static or object-store data.	Add linked gene, cell-state, donor, heatmap and spatial views after qualified AnnData-Zarr objects are registered.	Do not add a viewer before donor-aware, checksum-addressed objects exist.	Future linked cell browser	The visual layer would inherit NMD-VCell evidence states and donor-aware statistical rules.	No production AnnData-Zarr or Vitessce view configuration is registered for DMD tissue data.	VISUAL_PATTERN_VERIFIED_DATA_PREPARATION_BLOCKED	https://vitessce.io/docs/
LANDSCAPE-VCELL	VCell Modeling & Analysis Software	MECHANISTIC_SIMULATION	ADJACENT	Systems and computational biologists	Build and simulate a mechanistic model	MECHANISTIC_SIMULATION	OPEN_SOURCE	NO	GENERAL_BIOLOGY	HIGH	P2	Separates biological model definition, applications, parameters, geometry, numerical solvers, simulation runs and downloadable results across deterministic and stochastic methods.	Keep evidence checks, learned response models and future mechanistic solvers as distinct object classes with equations, parameters and run logs.	Do not relabel an evidence graph as a calibrated mechanistic simulation.	DMD process map | Future mechanistic solver lane	NMD-VCell begins from disease evidence and the experiment needed to establish a modelable transition.	No calibrated mechanistic DMD model, parameter set or numerical simulation result is released.	OBJECT_SEPARATION_ADOPTED_SOLVER_LAYER_LOCKED	https://vcell.org/ | https://github.com/virtualcell/vcell
LANDSCAPE-TAHOE	Tahoe · Mosaic · Tahoe-100M	PERTURBATION_DATA_ENGINE	DIRECT	Virtual-cell model builders and drug discovery teams	Access a large chemical perturbation atlas	PROPRIETARY_DATA_ENGINE_WITH_OPEN_RELEASES	MIXED	YES	CANCER_FIRST	MEDIUM	P1	Builds large perturbational single-cell maps and publishes Tahoe-100M as a reusable data product with manuscript, download, community and model entry points.	Treat every important disease dataset as a versioned product with a scientific question, access path, limitations, examples and downstream model links.	Do not use cell-count scale as a substitute for donor, disease and perturbation relevance.	Measured DMD evidence release | Dataset cards	NMD-VCell can make donor structure, neuromuscular context and claim ceilings more visible than a scale-first perturbation atlas.	No flagship NMD perturbation dataset currently connects a public Dataset Card to measured outcomes, model runs and follow-up studies.	DATA_PRODUCT_PATTERN_ADOPT_NOW_SCALE_NOT_INHERITED	https://www.tahoebio.ai/ | https://www.tahoebio.ai/news/open-sourcing-tahoe-100m
LANDSCAPE-XAIRA-XCELL	Xaira Therapeutics · X-Cell	CAUSAL_PERTURBATION_MODEL	DIRECT	AI drug discovery researchers	Evaluate or apply a cross-context perturbation model	PROPRIETARY_PERTURBATION_DATA_AND_MODEL	MIXED	YES	GENERAL_CELL_CONTEXTS	MEDIUM	P1	Packages a virtual-cell release around a named model, a large perturbation training asset, a technical report and a cross-context prediction task.	Give each locally evaluated model a permanent release page that binds model version, training context, target context, artifacts, benchmark results and limitations.	Do not claim cross-context DMD generalization without prospective disease-relevant validation.	Model card audit | ModelRun release objects	NMD-VCell publishes negative runs, abstentions and disease-specific transfer boundaries instead of relying on a broad model launch claim.	Model releases are audited, but the public product does not yet present every ModelRun as one linked release package with quickstart and failure analysis.	MODEL_RELEASE_CONTRACT_ADOPT_PERFORMANCE_NOT_INHERITED	https://www.xaira.com/news/announcing-x-cell-our-virtual-cell-model-trained-on-billions-of-genomic-data-points | https://www.cdn.xaira.com/papers/X_CELL_V1_0316_final.pdf
LANDSCAPE-RECURSION-OS	Recursion OS · Predict–Explain–Discover	LAB_IN_THE_LOOP_DRUG_DISCOVERY	DIRECT	Drug discovery programs	Move from perturbation maps to a therapeutic program	AUTOMATED_LAB_DATA_MODEL_LOOP	PROPRIETARY	YES	THERAPEUTIC_PROGRAMS	MEDIUM	P0	Connects automated perturbation experiments, phenomics and transcriptomics, learned maps, design workflows and downstream therapeutic programs in a physical-to-digital feedback loop.	Show the complete lifecycle from experimental material through assay, data object, model, decision, new experiment and evidence update.	Do not imply an automated wet-lab or therapeutic pipeline that NMD-VCell does not operate.	Evidence-to-experiment loop | Study Cards | Outcome registry	NMD-VCell can expose each evidence transition and missing link publicly even without proprietary lab scale or a drug pipeline.	Study Cards and an outcome registry exist, but no measured candidate-level DMD outcome has yet completed the loop.	CLOSED_LOOP_SCHEMA_ADOPTED_MEASURED_RETURN_PENDING	https://www.recursion.com/platform | https://arxiv.org/abs/2505.14613
LANDSCAPE-GENBIO-AIDO	GenBio AI · AIDO	MULTISCALE_WORLD_MODEL	DIRECT	Multiscale biological AI researchers	Use or combine biological foundation models	MULTISCALE_MODEL_SYSTEM	MIXED	NO	GENERAL_BIOLOGY	LOW_TO_MEDIUM	P2	Frames DNA, RNA, protein, structure and single-cell models as interoperable modules on a roadmap toward a multiscale biological world model.	Publish a layered capability roadmap that distinguishes released modules, interfaces between scales and future simulation goals.	Do not use world-model language where only bounded evidence objects are available.	Meaning map | Capability atlas	NMD-VCell can make every currently supported scale and unsupported transition explicit rather than presenting a universal world-model claim.	Gene, pathway, cell-state and experiment objects are linked conceptually but do not yet share one typed cross-scale relation contract.	ROADMAP_PATTERN_ADOPT_UNIVERSAL_CLAIM_REJECTED	https://genbio.ai/ | https://genbio.ai/world-model-of-the-virtual-cell/
LANDSCAPE-CELLULAR-INTELLIGENCE	Cellular Intelligence	TEMPORAL_SIGNALING_ACTIVE_LEARNING	DIRECT	Regenerative medicine and cell engineering teams	Design temporal signaling interventions	SEQUENTIAL_SIGNALING_DATA_ENGINE	PROPRIETARY	YES	CELL_FATE	LOW_TO_MEDIUM	P1	Emphasizes sequential signaling, dose, temporal order, cell-fate control and active learning over static cell-state representation.	Represent intervention sequence, dose and time as first-class variables, then prioritize experiments by the uncertainty they can resolve.	Do not inherit company-reported scale or efficiency claims as validated evidence.	DMD process map | Experiment Planner	The DMD process map and Study Cards can connect temporal signaling hypotheses to source-linked disease evidence and explicit outcome branches.	Current studies record time and endpoint, but the planner does not yet compare sequential interventions or information gain across an experiment portfolio.	TEMPORAL_CONTRACT_NEXT_ACTIVE_LEARNING_FUTURE	https://www.cellularintelligence.com/news/somite-becomes-cellular-intelligence
LANDSCAPE-CELLARIUM	Broad Cellarium AI	SINGLE_CELL_DATAOPS_MLOPS	INFRASTRUCTURE	Single-cell computational teams	Run a task-specific single-cell tool	DATAOPS_MLOPS_AND_TOOLING	OPEN_RESEARCH	NO	GENERAL_BIOLOGY	HIGH	P0	Presents annotation, denoising, perturbation interpretation and cloud infrastructure as separate tools with task-specific identities.	Turn existing NMD-VCell pages into a tool catalog only when each module has declared inputs, outputs, failure states, examples and machine interfaces.	Do not label an informational page as a tool without executable inputs and outputs.	Resolver | Compare | Process inspector | Model auditor | Planner	NMD-VCell can bind each tool output to disease evidence, a claim ceiling and the next experiment instead of ending at a generic analysis artifact.	Resolver, comparator, process inspector, model auditor and planner exist but do not yet share a visible tool contract.	TOOL_CATALOG_CONTRACT_IMPLEMENT_THIS_BUILD	https://www.cellarium.ai/
LANDSCAPE-NVIDIA-BIONEMO	NVIDIA BioNeMo	MODEL_DEPLOYMENT_INFRASTRUCTURE	INFRASTRUCTURE	AI developers and enterprise research teams	Build, adapt or deploy a biology model	COMPUTE_PACKAGING_AND_DEPLOYMENT	MIXED	NO	DRUG_DISCOVERY	MEDIUM	P1	Packages biomolecular AI capabilities as frameworks, web interfaces, APIs and deployable inference microservices.	Keep one model identity across web documentation, API records, local adapters, artifacts and deployment-specific run receipts.	Do not build enterprise infrastructure before a reproducible disease adapter is needed.	API | Model adapters | Run receipts	NMD-VCell can provide stronger disease-specific evidence governance around externally executed or locally adapted models.	The public API exposes ModelRuns, but there is no uniform adapter package or deployment receipt across external model families.	PACKAGING_CONTRACT_NEXT_INFRASTRUCTURE_NOT_REQUIRED	https://www.nvidia.com/en-us/clara/bionemo/